Founded in 2007, Regeneus Ltd (ASX: RGS) is a regenerative medicine company based in Sydney. The company targets unaddressed medical needs in human and deals in the development of a portfolio of innovative cell-based therapies, with a primary focus on neuropathic pain, osteoarthritis (OA) and dermatology. Mr Leo Lee is the current Chief Executive Officer of the company.
All products in the company’s pipeline are backed by proprietary stem cell technologies, and these technologies use mesenchymal stem cells (MSCs) from adipose tissue. MSCs reduce inflammation, promote tissue repair and reduce scarring, thereby enabling the natural healing of the body.
Let us have a look at the company’s key therapeutic areas and the respective technologies used for their treatment.
For the treatment of osteoarthritis and other musculoskeletal disorders, the company has developed a cell therapy technology ‘Progenza’. The Phase I trial of the ‘Progenza’ (STEP Trial) has been successfully completed. The technology met primary safety endpoints and was found effective in easing knee pain and enhancing cartilage volume.
In 2018, the company collaborated with a Japanese biopharmaceutical manufacturer AGC to get the exclusive rights for the development of Progenza for all. For the development of ‘Progenza’, Regeneus has initiated preparations for the proposed Phase II clinical trial of Progenza’ for osteoarthritis in Japan.
Targeting solid tumour types, the company has manufactured a vaccine ‘RGSH4K’ from a patient’s own cancer cells. The vaccine is at present being used in Phase 1 clinical trial (ACTIVATE Trial). The company is exploring the opportunity for combining ‘RGSH4K’ with checkpoint inhibitors.
Skin Conditions & Wound Healing
A topical application, ‘Sygenus’ has been manufactured for the treatment of acne, wound healing and inflammatory skin conditions.
Canine osteoarthritis and tendinopathy
Besides Human Osteoarthritis, Regeneus has also developed a cell therapy technology ‘CryoShot Canine’ for the treatment of canine osteoarthritis. The technology is currently being evaluated in a pre-pivotal trial.
Regeneus has manufactured a vaccine ‘Kvax’ to commence a systemic immune response and successfully fight the cancer cells. The vaccine is being evaluated in a clinical trial for its use in combination with chemotherapy in treating canine lymphoma.
Let’s take a look at company’s recent announcements:
The company has recently announced the appointment of two independent, Non-Executive Directors – John Chiplin, PhD and Alan W. Dunton, M.D. to its Board of Directors.
Regeneus presented its half-year report for the half-year ending 31st December 2018 in late February. The company reported a revenue of $14,863 and witnessed a significant reduction in corporate expenditure in the half-year period to 31st December 2018 in comparison to the prior year.
Loan Funding Announcement
In February this year, the Board of Directors of Regeneus provided a loan of $2.5 million for a term of 12 months to extend the company’s funding runway. The funding was led by the Regeneus CEO, Mr Leo Lee.
Stock Performance: The stock last traded at AUD 0.110 on 17th May 2019. In the last one-month, the stock has delivered 4.76% return.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.